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ABSTRACT
Thyroid hormones (THs) – 3,3′,5-triiodo-L-thyronine (T3) and L-thyroxine (T4) 
– are important regulators of the metabolism and physiology of most normal tissues. 
Cytochrome P450 family 3A members are drug metabolizing enzymes involved in the 
activation and detoxification of several drugs. CYP3A4 is the major enzyme involved 
in the metabolism of chemotherapeutic drugs. In this work, we demonstrate that 
THs induce a significant increase in CYP3A4 mRNA levels, protein expression and 
metabolic activity through the membrane receptor integrin αvβ3 and the activation of 
signalling pathways through Stat1 and NF-κB. We reasoned that TH-induced CYP3A4 
modulation may act as an important regulator in the metabolism of doxorubicin 
(Doxo). Experiments in vitro demonstrated that in CYP3A4-knocked down cells, no  
TH-mediated chemosensitivity to Doxo was observed. We also found that THs modulate 
these functions by activating the membrane receptor integrin αvβ3. In addition, we 
showed that the thyroid status can modulate CYP450 mRNA levels in tumor and liver 
tissues, and the tumor volume in response to chemotherapy in vivo. In fact, Doxo 
treatment in hypothyroid mice was associated with lower tumors, displaying lower 
levels of CYP enzymes, than euthyroid mice. However, higher mRNA levels of CYP 
enzymes were found in livers from Doxo treated hypothyroid mice respect to control. 
These results present a new mechanism by which TH could modulate chemotherapy 
response. These findings highlight the importance of evaluating thyroid status in 
patients during application of T-cell lymphoma therapeutic regimens.
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INTRODUCTION
T-cell lymphomas (TCL) are a heterogeneous 
group of aggressive lymphoproliferative disorders with 
considerable clinical, morphological, immunophenotypic 
and genetic variation, including approximately 10–15% of 
all lymphoid neoplasms [1]. Despite producing less than 
satisfactory results, the combination of cyclophosphamide, 
doxorubicin, vincristine and prednisone (CHOP) remains 
the standard treatment for TCL [2]. This therapeutic 
approach, originally designed for B-cell lymphomas, has 
poor outcome with common recurrence and few effective 
options for rescue therapy [2, 3]. This fact clearly points out 
the importance of identifying therapies to improve disease 
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outcome. Cytochrome P450 family 3A members (CYP3A4, 
5, 7 and 43) are drug metabolizing enzymes involved in the 
activation and detoxification of several drugs [4]. Due to 
its ability to activate or inactivate chemotherapeutic drugs, 
the expression of CYP has been proposed as a biomarker of 
the clinical evolution in patients treated with chemotherapy 
[5]. Moreover, CYP enzymes have been shown to either 
activate some anticancer drugs, or to inactivate other 
anticancer agents [6]. Although the regulation of CYP 
enzymes exerted by hormonal nuclear receptors has been 
well studied [7], few studies have explored the regulation 
of these genes by thyroid hormones and their receptors in 
pathological conditions.
Thyroid hormones (THs), 3,5,3′-triiodo-L-thyronine 
(T3) and L-thyroxine (T4), are essential regulators of the 
differentiation, growth, metabolism and physiological 
functions of most normal tissues. In our previous work 
we have shown that THs have been implicated in cell 
transformation, tumorigenesis, angiogenesis [8]; and 
metastatic spread [9]. Particularly, it has been shown that 
THs action on these biological processes can be mediated 
through its nuclear TRα receptor, but also via nongenomic 
mechanisms, involving cell surface membrane receptors 
(mTR) such as integrin αvβ3 and cytoplasmic located TR 
[10–14]. In vitro studies carried out in our laboratory have 
shown that THs, via a membrane receptor, could modulate 
the balance between proliferation and viability versus 
apoptosis of TCL cells involving different intracellular 
signaling pathways like p42/44 MAPKs, PKC, and NF-kB 
[8, 15–17]. In this sense, other authors have shown a nuclear 
association between integrin αv, phosphorylated p42/44 
MAPKs and Stat1 in T4-stimulated OVCAR-3 cells [18].
There are some studies describing genetic 
polymorphisms of CYP enzymes in patients with Non-
Hodgkin’s lymphomas [19], as well as the association 
between side effects of drugs for leukemia treatment and 
the expression of these enzymes [20]. However, studies 
evaluating the regulation of CYP enzymes by THs and the 
response to the therapy were not performed yet. 
In this study, we analyzed the effect of THs on 
therapy response and the modulation of enzymes involved 
in the metabolism of chemotherapeutic drugs. We here 
show, for the first time, that THs can induce CYP3A4 
expression in TCL cells, having different effects on CHOP 
drugs depending on whether their metabolites are active 
or inactive, Furthermore, these effects were confirmed 
in vivo and the relevance of the patient thyroid status in 
chemotherapy outcome was discussed here as well. 
RESULTS
THs induce chemo-sensitivity to doxorubicin in 
TCL cells 
To assess the effect of THs on the response 
to conventional chemotherapy, we treated Jurkat 
cells with increasing doses of doxorubicin (Doxo) 
and vincristine (VCR) in presence or absence of 
physiological concentrations of T3 and T4 (1 nM and 
100 nM, respectively) to mimic circulating levels of both 
hormones. We used these two chemotherapeutic drugs as 
Doxo render an active metabolite, while VCR metabolite 
is inactive [21]. As expected, Doxo and VCR induce 
cytotoxicity in TCL cells treated or not with THs (Figure 
1A and 1B). Doxo significantly decreased cell viability in 
a dose-dependent manner, and this effect was even greater 
in presence of THs (Figure 1A). On the other hand, VCR 
effects on cell viability were reverted when Jurkart cells 
were pretreated with THs (Figure 1B). Similar results were 
found in Doxo-treated OCY-Ly12 cells (Figure 1C), Hut78 
(Figure 1D) and in the murine lymphoma T cell line EL4 
(Figure 1E).
Considering the results shown above, we investigated 
the metabolizing enzymes of chemotherapeutic drugs. 
Thus, we evaluated THs regulation of CYP3A family 
members (CYP3A4, CYP3A5, CYP3A7, and CYP3A43). 
We found that every CYP3A gene was significantly 
modulated by THs in Jurkat cells treated for 18 h 
(Figure 2A). In mice, CYP1A1, CYP1A2, CYP2b10 and 
CYP3A11 isozymes have been described as responsible for 
the metabolism of xenobiotic compounds [22]. The mRNA 
levels of the four enzymes were up-regulated in vitro by 
THs in EL4 cells (Figure 2B). 
Since CYP3A4 metabolizes more than 50% of drugs 
currently used in chemotherapy [4] and its expression in 
peripheral T-cell lymphoma (PTCL) is associated with a 
shorter survival rate [5], we focused our experiments on 
this member of the CYP3A family. In this line, to elucidate 
the participation of THs classic and nongenomic effects 
we performed in vitro assays with THs or THs-coupled 
to agarose (TH-AG), the latter unable to pass through the 
plasma membrane and thus binding exclusively to the 
mTR, the integrin αvβ3 [17]. Treatment with both THs 
and TH-AG for 6 h-induced a significant increase on 
CYP3A4 mRNA synthesis (Figure 2C). Similar results 
were found in CUTLL1, OCI-Ly12 and Hut78 cell lines 
(Figure 2D). In addition, 24 h treatment with physiological 
concentrations of THs and TH-AG increased protein 
levels of CYP3A4 by western blot assays in Jurkat cells 
(Figure 2E). These results are in line with those obtained 
for CYP3A4 mRNA levels, suggesting that THs induce 
modulation at both mRNA and protein CYP3A4 levels. 
We have previously demonstrated the functionality 
of integrin αvβ3 as membrane receptor for TH-induced 
angiogenesis and proliferation in TCL cells [8]. To 
confirm that integrin αvβ3 is critical on TH-induced 
CYP3A4 expression, we performed experiments 
inhibiting expression of this integrin. For this purpose, 
Jurkat cells were transfected with si-ITGAV+si-ITGB3. 
Down-regulation of the integrin αvβ3 inhibited both 
THs and TH-AG-induced CYP3A4 mRNA expression 
(Figure 2F). Similar results were found in EL4 cells treated 
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with cilengitide, a cyclic RGD pentapeptide that inhibit 
αvβ3 integrin [23] (Figure 2G). 
We then analyzed whether TH-dependent increase 
on CYP3A4 protein levels could modulate its enzymatic 
activity assayed by P450-Glo kit assay. As shown in Figure 
2H, THs induced metabolic activation of CYP3A4 respect 
to untreated cells reaching similar levels to those induced 
by dexamethasone, a well-known CYP3A4 inducer [24]. 
Also, CYP3A4 inhibitor ketoconazole [25] prevented TH-
induced CYP3A4 activation. In the presence of cilengitide, 
THs were not able to induce CYP3A4 enzymatic activity 
(Figure 2H). 
THs and agarose-coupled THs induce signaling 
pathway activation in TCL cells
Our group has previously demonstrated that THs and 
TH-AG induce p42/44 MAPK phosphorylation and NF-κB 
activation down-stream PKCζ in murine T lymphoma cells 
[15]. In addition, we have previously demonstrated that 
THs induce NF-κB activation and nuclear translocation in 
human TCL [8]. As shown in Figure 3A and 3B, THs and 
TH-AG significantly increased NF-κB phosphorylation 
in Ser 536. Previous work showed that THs induce Stat1 
phosphorylation [26]. In this sense, here we show that THs 
Figure 1: Thyroid hormones sensitize T lymphoma cells to doxorubicin treatment. Jurkat cells were pretreated or not (ct) 
with THs for 18 h before treatment with different doses of Doxo (A) or VCR (B). OCI-Ly12 (C), Hut78 (D) and El4 (E) cells were 
pretreated or not (ct) with THs for 18 h before treatment with different doses of Doxo. Cell Titer Blue assay determined the number of live 
cells at each dose. Data are shown as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 respect to untreated cells.
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Figure 2: Thyroid hormones modulation of CYP P450 levels. Role of the integrin αvβ3 TH membrane receptor. (A) mRNA 
levels of CYP3A4, CYP3A5, CYP3A7 and CYP3A43 were analyzed by qPCR in Jurkat cells treated with THs or TH-AG for 18 hs. 
(B) mRNA levels of CYP1a1, CYP1a2, CYP2b10 and CYP3a11 were analyzed by qPCR in EL4 cells treated with THs or TH-AG for 18 hs. 
(C) mRNA levels of CYP3A4 were analyzed by qPCR in Jurkat cells treated with THs or TH-AG for the indicated times. (D) mRNA levels 
of CYP3A4 were analyzed by qPCR, in Jurkat, CUTTL1, OCI-Ly12 and Hut78 cells treated with THs or TH-AG for 18 hs. (E) Jurkat cells 
were treated with THs, TH-AG, AG (ct-AG) or remained untreated (ct) for 24 h. Western Blot analysis shows CYP3A4 levels. GAPDH 
was used as loading control. Top panel: representative data from 1 of 3 independent experiments. Bottom panel: densitometric analysis. 
(F) Jurkat cells transfected with non-target siRNA (siNT, control), anti-integrin αv + anti-integrin β3 siRNA (siITGAV+ITGB3) were 
treated with THs, TH-AG or remained untreated for 18 h. mRNA levels of CYP3A4 were analyzed by qPCR. (G) mRNA levels of CYP1a1 
and CYP2b10 were analyzed by qPCR in EL4 cells treated with THs, THs + 1,5 mM cilengitide. (H) CYP3A4 enzymatic activity was 
measured using P450-Glo kit Assays in Jurkat cells that were treated or not with THs, THs + 1,5 µM cilengitide, THs + 1 µM ketoconazole 
or 50 µM Dexametasone for 48 h. Data are shown as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 vs. untreated cells (ct, dash line), 
#p < 0.01 vs. THs treated cells.
Oncotarget3055www.oncotarget.com
and TH-AG induced Stat1 phosphorylation in Tyr 701, as 
well (Figure 3A and 3B). Both THs and TH-AG induced 
Stat1 nuclear translocation (Figure 3C).
Giving that TH-AG are not able to enter the cell, 
these results suggest the activation of a membrane receptor 
that induces intracellular signaling pathways. To confirm 
that integrin αvβ3 is the membrane receptor involved in 
TH-induced signaling pathway, we evaluated the effect 
of THs in integrin αvβ3-depleted cells. We found that 30 
min of TH-AG were not able to induce neither Stat1 nor 
NF-κB (Figure 3D). As expected, the NF-κB inhibitor 
(BAY-11-7082) and treatment with si-Stat1 impairs both 
THs and TH-AG-induced expression of CYP3A4 mRNA 
(Figure 4A and 4B). 
TH-mediated Doxo chemosensitivity occurs 
through integrin αvβ3 activations and CYP 
modulation
To corroborate the biological significance of 
TH-induced CYP3A4 expression through the integrin 
αvβ3 in Doxo sensitization, we analyzed cell viability. 
Figure 3: Thyroid hormones induce Stat1 and NF-kB activation. Jurkat cells were treated with THs (A), TH-AG (B) or remained 
untreated (ct) for the indicated times. Western Blot analysis show Stat1-Y701-phosphorylation and NF-kB-S536-phosphorylation levels. 
GAPDH was used as loading control. Top panel: representative data from 1 of 3 independent experiments. Bottom panel: densitometric 
analysis. (C) Representative photograph of pStat1 nuclear localization as analyzed by IF and confocal microscope an cells treated with THs, 
TH-AG, or untreated (control) for 15 min. (D) Cells transfected with non-target siRNA (siNT) or anti-integrin αv + anti-integrin β3 siRNA 
(siITGAV+ITGB3) were treated with TH-AG or remained untreated for 30 min. Western Blot analysis show Stat1-Y701-phosphorylation 
and NF-kB-S536-phosphorylation levels. GAPDH was used as loading control. Top panel: representative data from 1 of 3 independent 
experiments. Bottom panel: densitometric analysis. Data are shown as mean ± SD. **p < 0.01; ***p < 0.001 vs. untreated cells.
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As shown in Figure 4C, in presence of integrin αvβ3 
inhibitior cilengitide, THs did not sensitize Jurkat cells 
to Doxo, reaching the same level as ketoconazole, a 
pharmacological inhibitor of CYP3A4. Similar results 
were found in Hut78 and El4 (Figure 4D and 4E). In the 
same way, inhibiting the expression of CYP3A4 with 
siRNA, THs were unable to sensitize Jurkat cells to Doxo 
treatment (Figure 4F). These results suggest that THs 
Figure 4: Thyroid hormones modulate CYP3A4 expression and TH-induced doxorubicin  chemo-sensitivity. (A) Cells 
were pre-treated with vehicle or BAY 11-7082 (2.5 µM) and then treated for 18 with THs, TH-AG, or remained untreated (control, dash 
line). We analyzed mRNA levels of CYP3A4 on these conditions. (B) mRNA levels were measured on cells previously transfected with 
non-target siRNA (siNT) or anti Stat1 siRNA (siStat1) and then incubated with THs or TH-AG as indicated above. Data are shown as mean 
± SD. ***p < 0.001 respect to untreated cells. Cell Titer Blue assay was performed in Jurkat (C), HuT78 (D) and El4 (E) cells pre-treated 
with THs, TH + cilengitide 1.5 µM or THs + ketoconazole 1 µM for 6 h or remained untreated (ct) and then treated with Doxo 1 µM for 
24 h, and Jurkat cells (F) transfected with siNT or anti CYP3A4 siRNA (siCYP3A4) were pre-treated or not (ct) with THs for 6 h and then 
treated with Doxo 1 µM for 24 h. Data are shown as mean ± SD. ***p < 0.001 respect to ct. 
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modulate the CYP3A enzyme through its non-classical 
membrane receptor affecting the efficacy of Doxo.
Thyroid status impact on cytochrome P450 
expression in vivo and affect therapy response
In previous sections, we described how THs 
induce CYP3 in vitro regulation in human and murine 
TCL cells and its importance in Doxo metabolism. To 
address whether circulating levels of THs modulate CYP 
expression and Doxo response, we evaluate tumor growth 
in tumor-bearing euthyroid (Eu) and hypothyroid (Hypo) 
mice. EL4 lymphoma cells were inoculated in syngeneic 
mice with different thyroid status as previously described 
[9]. T3, T4, and TSH plasma levels were determined to 
check the efficacy of T4 and PTU treatments. As previously 
reported by our group [9], hypothyroid mice showed lower 
T3 and T4 levels, but higher levels of TSH than euthyroid 
mice (Figure 5A). After EL4 cell inoculation all animals 
developed solid tumors. When the tumors reached a 
palpable size, mice of each thyroid status were randomly 
separated in two groups: one remains untreated (Eu and 
Hypo) and the others were treated with Doxo (Eu+Doxo 
and Hypo+Doxo). At day 14 post injection (p.i.), Eu+Doxo 
mice showed a significant decrease in EL4 lymphoma 
growth compared with tumors in control euthyroid mice 
(Figure 5B) indicating the effectiveness of Doxo treatment. 
As we had previously reported, Hypo mice did not show 
significant differences in tumor volume respect to the Eu 
mice [9], but Doxo was also effective in these mice as well. 
However, unlike what we expected according to our in vitro 
results of viability, the tumor volume in Hypo+Doxo mice 
was significantly lower than Eu+Doxo mice (Figure 5A). 
To elucidate whether THs circulating levels modulate 
Doxo-response, mRNA from tumors was extracted from 
mice with different thyroid status and CYP expression was 
analyzed. As seen in Figure 5C, Doxo decreased mRNA 
levels of the analyzed isozymes both in euthyroid and 
hypothyroid conditions. However, Doxo-mediated decrease 
in Hypo mice was significantly lower than Eu+Doxo mice 
(Figure 5D). As in vivo CYP metabolism, is mainly related 
to the higher protein content of CYP in adult liver [4], we 
evaluated hepatic CYP mRNA levels in Doxo-treated mice 
with normal or low levels of THs. In the liver, a significant 
increase in the four CYP enzymes was found under 
hypothyroid conditions respect to euthyroidism (Figure 
5D). So, higher hepatic metabolism of CYP in Hypo-
Doxo mice, rendering high circulating levels of the active 
metabolite, would account for the low tumor volumes 
found in this condition, thus pointing out the importance of 
thyroid status on chemotherapy outcome. 
DISCUSSION
The knowledge of the molecular mechanisms leading 
to tumor chemotherapy resistance is crucial to assure the 
success of treatment. Among these mechanisms, factors 
that influence CYP expression and function play an 
important role. In this work, we demonstrate the regulatory 
role of THs, at the physiological concentrations found in 
tumor microenvironment, on response to Doxo in TCL 
cells. This effect is mediated by Stat1 and NF-κB activation 
leading to CYP3A4 expression and to the up-regulation 
of its enzymatic activity. The viability studies revealed 
that under proliferative conditions pretreatment with THs 
sensitizes Jurkat cells to Doxo treatment, but not to VCR. 
This could be related to the fact that Doxo metabolites are 
active while this is not the case with VCR [21].
The cytochrome P450 is a large and diverse 
superfamily of hemoproteins using a wide range of 
exogenous and endogenous compounds as substrates 
for their enzymatic reactions. The CYP3A subfamily, 
consisting of the isozymes CYP3A4, CYP3A5, CYP3A7 
and CYP3A43 is responsible for the metabolism of 
approximately 50% of the drugs currently used [4]. All 
members of CYP3A family were found up-regulated by 
THs in TCL cells. Being CYP3A4 the major enzyme 
involved in the metabolism of chemotherapeutic drugs, 
we reasoned that TH-induced CYP3A4 metabolic activity 
may act as an important regulator in the metabolism 
of Doxo in our experimental conditions. Here we 
demonstrate that THs induce CYP3A4 expression through 
the activation of non-classical THs receptors, namely the 
integrin αvβ3 as demonstrated by the genomic down-
regulation of the mTR. In concordance, our previous 
work demonstrates that THs exert non-classical actions 
through the integrin αvβ3 in several TCL cell lines 
[8]. THs are present in the cell microenvironment and 
can exert nongenomic actions in a short period of time 
[11]. The nongenomic mechanism of action of THs are 
generally mediated by rapid signaling pathways including 
the activation of PKC, PKA, PI3K, protein kinase, 
MAPK and the activation of PLC, among others [11, 12]. 
Additionally, THs may alter intracellular trafficking and 
the phosphorylation of TR, ERα, Stat1 and p53, through 
the integrin αvβ3 pathway [27] and nuclear interaction of 
Stat1 with the integrin αv monomer in ovarian cancer cells 
[18]. Previous work from our laboratory shows that THs 
can stimulate the proliferation of murine TCL via THs 
binding to its membrane receptor and activating NF-κB as 
a transcription factor [17]. Furthermore, it was shown that 
the THs acting at physiological concentrations can induce 
angiogenesis and proliferation of human mature and 
immature TCL. In summary, our results indicate that THs 
acting through its membrane receptor integrin αvβ3 can 
activate the transcription factors Stat1 and NF-κB leading 
to the increase CYP3A4 expression levels downstream. 
We found that cilengitide impairs THs sensitization 
of TCL cells to Doxo treatment. Cilengitide, is a small 
cyclic peptide ligand, that recognized RGD extracellular 
domain of integrin αvβ3, currently used in clinical studies 
[23]. Promising results were found in advanced solid 
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tumors treated in combination with paclitaxel [28] and 
chemoradiotherapy [29]. These results are in concordance 
with the fact that THs are not able to induce CYP3A4 
expression in the presence of integrin αvβ3 down-
regulation. 
The proposed molecular mechanism by which THs 
induce CYP3A4 modulation is depicted in Figure 6. T3 
and T4 interacting with integrin αvβ3 in the membrane 
cell induce Stat1 and NF-κB phosphorylation and nuclear 
translocation leading to CYP3A4 expression. It is important 
to note, that in silico analyzes (Genomatix genome 
analyser -MatInspector. http://www.genomatix.de.) 
strengthen the fact that THs action on CYP is indirect via 
the participation of transcription factors activated through 
Figure 5: Effect of thyroid status on murine cytochrome P450 expression and tumor response to chemotherapy. 
(A) Plasma levels of THs in Euthyroid, Hyperthyroid, and Hypothyroid mice were determined using ELISA. #p < 0.05 (B) Euthyroid, and 
hypothyroid mice were subcutaneously inoculated with 3 × 105 EL4 cells (n = 5 for each group). When tumors were palpable, mice were 
randomized and treated or not with Doxo. Tumors growth from day 7 to 16 post inoculation was measured by the AUC. Data are shown as 
mean ± S.E.M *p < 0.05 respect to Hypothyroid animals, **p < 0.01 respect to euthyroid animals or ***p < 0.001 respect to Euthyroid+Doxo 
animals. mRNA expression of murine CYP P450 1A1, 1A2, 2b10 and 3A11 was determined in tumor and liver tissues (C and D) by qPCR 
analysis. Gene expression was normalized to β-2-microglobulin gene, and the ∆∆Ct method was used to calculate the fold change. Data are 
shown as mean ± S.E.M **p < 0.01 or ***p < 0.001.
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the membrane receptor, as these assays indicate an absence 
of THs response elements (TRE) in the CYP3A4 proximal 
promoter.
In this work, in addition to THs involvement in 
CYP3A4 expression and activation, we also demonstrate 
a THs role in response to chemotherapeutic drugs. Both 
Doxo and VCR are metabolized by enzymes of the 
CYP3A family, being CYP3A4 the primary isoforms that 
mediate their biotransformation [30]. In the case of Doxo, 
CYP3A4-mediated metabolism leads to drug activation, 
whereas VCR is inactivated [21]. Doxo is metabolized 
by liver CYP450 enzymes which release the activated 
metabolite into the systemic circulation with therapeutic 
activity, but also with associated host cell toxicity [31]. 
The effectiveness of Doxo in destroying cancer cells 
have been widely shown; however, due to off-target 
complications as cardiomyopathies, it should be use dose-
limited [32]. CYP3A isoforms are mainly expressed in the 
liver [33], however, some specific isoforms are further 
expressed extrahepatically [34, 35]. The expression of 
different CYP3A genes was demonstrated in a subset 
of PTCL tumors [5], and also in various cancers, 
including breast, lung, colon and those of the head and 
neck, showing differential expression of CYP450 levels 
in tumor relative to normal tissue [36–39]. In this way, 
several authors have proposed the P450-Based Gene-
Directed Enzyme Prodrug Therapy to potentially enhance 
the efficacy of P450-activated anticancer prodrugs, 
without increasing host toxicities [40–44]. In this work 
we showed that the thyroid status can modulate the in 
vivo response to Doxo and CYP levels both in tumor 
and liver tissue. In fact, tumor-bearing hypothyroid mice 
display a greater response to Doxo treatment with smaller 
tumors than euthyroid Doxo-treated mice. To this end, 
thyroid status regulation of CYP enzymes was evaluated 
showing that Doxo decreased CYP levels both in tumors 
of mice with euthyroidism and with hypothyroidism, 
being significantly lower in the latter. This would agree 
with the increase in CYP levels induced in vitro in EL4 
cells by THs. Additionally, this would also be related to 
the tumor volume found in Hypo+Doxo mice, as a low 
biotransformation of the active metabolite is expected.
Other authors have reported hypothyroidism as a 
positive prognostic factor for the outcome of the disease 
in different types of cancer even when hypothyroidism 
occurs as a side effect of the treatment received [45, 46]. 
This could indicate that the lower tumor growth seen in 
Doxo-treated hypothyroid mice is due to the effect of the 
Figure 6: Proposed mechanisms for the effects of thyroid hormones on the CYP3A4 expression. THs interact with the 
receptor integrin αvβ3 on the cancer cell membrane and activate intracellular pathways. Purple arrows depict PKC and ERK pathways 
described previously in TCL cells [8, 17, 58]. Black arrows show the signals here elucidated: THs induction of Stat1 and NF-κB activation. 
Once Stat1 and NF-κB are activated translocate to the nucleus where they act as transcription factors that lead to the genomic transcription 
of CYP3A4. The possible activation of NF-kb downstream Stat1 is also suggested (dotted arrow).
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thyroid status by itself. However in our model we have not 
seen differences in the tumor size between hypothyroid 
and euthyroid mice [9].
We even found that Hypo+Doxo mice have higher 
levels of CYP enzymes in the liver than Eu+Doxo, 
which would also point to higher circulating levels of 
the active metabolite, thus contributing to the low tumor 
volume found in response to Doxo in hypothyroid mice. 
In support to our results it has been shown that Doxo 
decreases the hepatic expression of CYP enzymes in rats 
[47] and that THs can decrease CYP levels in human 
hepatocytes in vitro [48], so it would be expected that 
low circulating levels of them may increase hepatic 
CYP. Moreover, the effect of thyroid function on the 
efficacy of cancer therapies has been described and 
hypothyroidism was suggested to have a positive impact 
on treatment outcome [45, 49, 50]. Furthermore, several 
authors have demonstrated shown that CYP3A4 has a 
differential expression in normal tissue vs tumor samples. 
Thus, Trujillo-Paolillo et al. [51] have demonstrated that 
Osteosarcoma biopsy specimens has lower CYP3A4 levels 
than normal bone specimens. Similar findings have been 
found for CYP3A4 in Hepatocellular Carcinoma tissues 
as compared to paired adjacent noncancerous liver tissues 
[52, 53].
In summary, we found that TH-mediated non-
classical actions could affect conventional chemotherapy 
outcomes. Together, these results highlight the importance 
of personalized medicine. The knowledge of the patient 
thyroid status and the possible modulation of drug 
metabolizing enzymes by thyroid hormones in the tumor 
could help to take a better choice of the chemotherapeutic 
regimen to each patient with the consequent success of 
the therapy.
MATERIALS AND METHODS
Preparation of T3 and T4 agarose-bound
Agarose-bound triiodothyronine and thyroxine 
hormones (T3-AG and T4-AG, respectively) were 
obtained as previously described [14]. Briefly, T3 and 
T4 were purchased from Sigma Chemical Co. (St. 
Louis, MI) and were used without further purification. 
N-Hydroxysuccinimide (NHS)-activated Sepharose 4 Fast 
Flow 14-atom spacer arm (between matrix and activated 
group) was obtained from GE Healthcare (formerly 
Amersham Biosciences, Uppsala, Sweden). Primary 
amino groups of the THs were coupled directly to active 
ester to form an amide linkage according to Amersham 
Biosciences. The contamination by T3 or T4 was always 
assessed by RIA assays and proved to be very low, less 
than 1 mol of free hormone per 105 or 104 mol of agarose-
coupled hormone, respectively. Moreover, stability of 
agarose-conjugated hormone in cell culture was assessed 
in supernatants from 24 h lasting cultures in the presence 
of either T3-AG or T4-AG that were depleted of cells and 
agarose by centrifugation, and non-detectable levels of 
free hormones were found.
Hormone determinations
Hormone determinations were done as previously 
described [54]. Briefly, blood was collected from the tail 
vein using a capillary tube coated with anticoagulant and 
plasma was obtained by centrifugation. The plasma levels 
of T3 and T4 were determined using commercial RIA 
kits with specific antibodies (Immunotech, Praga, Czech 
Republic) according to the manufacturer’s instructions. 
The plasma TSH level was assayed using an ELISA kit 
(Uscn Life Science, Inc., Wuhan, Hubei, Republic of 
China).
Cell viability assay
Cell viability was measured with a fluorimetric 
test as previously described [55]. Briefly, 
5 × 105 cells/ml were settled at a final volume of 0.1 ml 
in 96-well flat-bottom microtiter plates, and were treated 
or not for 24 hours with THs or agarose bound hormones 
as indicated in results. We used the fluorimetric resazurin 
reduction method (CellTiter-Blue; Promega) to evaluate 
the chemosensitivity of cells treated with doxorubicin or 
vincristine (Sigma Chemical Co., St. Louis, MI, USA). 
These drugs were added in a range of 0.25–10 µM or 0.005–
1 µM respectively in presence of THs or TH-AG into cells 
grown in 96-well plates and fluorescence (560Ex/590Em) 
was determined using a luminometer (NovoStar microplate 
reader, BMG Labtech). The percentage of viable cells was 
calculated by using the linear least-squares regression of 
the standard curve. Fluorescence was determined for 6 
replicates per treatment condition, and cell viability in TH-
treated cells was normalized to their respective controls.
T lymphoma cell lines
Jurkat, CUTLL1, HuT78 and OCI-Ly12 
were obtained as indicated previously [8]. 
Cells were cultured at optimal concentration 
(1–5 × 105 cells/ml) in RPMI 1640 (Invitrogen, Gibco, 
Grand Island, NY) supplemented with 10% FBS (Gibco 
BRL), 2 mM glutamine (Gibco BRL), and antibiotics 
(Gibco BRL). The tumor cell line EL4 (ATCC, 
Catalog Number TIB-39), a mouse T-cell lymphoma 
expressing the H-2b and Thy-1.2 haplotype, as well as 
the CD3+ and αβ T-cell receptors, was routinely tested 
by flow cytometry with specific antibodies against the 
corresponding surface markers. These cells were cultured 
at an optimal concentration (1–5 × 105 cells/ml) in 
RPMI-1640 medium supplemented with 10% v/v fetal 
bovine serum, 2 mmol/l glutamine, and 100 mg/ml of 
streptomycin (all from Life Technologies). We conducted 
monthly tests for Mycoplasma sp. and other contaminants 
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and quarterly cell identification by single-nucleotide 
polymorphism. Cells were treated at different times with 
THs or agarose-bound hormones (prepared as indicated 
above) at physiological concentration (T3 = 1 nM; 
T4 = 100 nM, Sigma Chemical Co., St. Louis, MI). Agarose-
bound hormones were used at the same concentrations 
than THs. Before treatments, cells were synchronized 
by serum starvation as previously indicated [8]. 
It is worth to note that cultures incubated with 
physiological concentrations of THs have free hormone 
concentrations consistent with normal physiological 
levels, as previously described [56–58].
Lymphoma model
C57Bl/6J mice were render hypothyroid 
in accordance with the protocol of Sterle et al. 
[9] by daily treatment with 0.5 mg/ml propylthiouracil 
(Sigma–Aldrich) in drinking water for 15 days. Euthyroid 
(with physiologic levels of circulating THs) or hypothyroid 
C57BL/6J animals were injected subcutaneously with 
syngeneic 3 × 105 EL4 cells in 200 ml PBS to generate 
a solid tumor. After cell inoculation, hormonal treatments 
were maintained until the end of the experiments. 
Once tumor reached a volume of 2 mm3, mice were 
randomized in two groups (n = 5 per group) control and 
Doxo treatment. Doxorubicin (2 mg/kg) was administered 
by intraperitoneal injection every day for 5 days. Tumor 
length and width were measured daily using calipers 
and volume was calculated by the equation V= (π/6) × 
length × width2. At the 14th day post inoculation, mice 
were sacrificed and tumors were excised. The animal 
experiments were approved by the Ethics Committee for 
the Use and Care of Laboratory Animals from BIOMED.
Transient transfections with siRNA
1 × 107 TCL cells were mixed with siRNA against 
ITGAV plus ITGB3, Stat1, CYP3A4 or a noncoding 
sequence (L-004565-00, L-004124-00, L-003543-00, 
L-008169-01, and D-001810-10, respectively, ON-
TARGETplus SMART pool, THERMO SCIENTIFIC) 
at a final concentration of 50 nM, and electroporated at 
250V for 15ms in a BTX ECM 830 electroporator. After 
transfection, cells were plated in RPMI 1640 medium 
supplemented with 10% SFB for 36 hours. The treatments 
corresponding to each test were then performed. 
Reverse transcription (RT) and quantitative (q)
PCR
Reverse transcription and qPCR was carried out 
as described previously [8]. Briefly, cells line samples 
were homogenized in Tri-Reagent (Genbiotech SRL) 
and total RNA was isolated following the manufacturer’s 
instructions. For the in vivo experiment, after the animals 
were killed, liver and solid tumors were removed and 
immediately homogenized in Tri-Reagent to isolate the 
RNA, according to the manufacturer’s instructions. cDNA 
was synthesized by retrotranscription using the Omniscript 
kit (Qiagen GMDH). cDNA amounts present in each 
sample were determined using a commercial master mix 
for Real-Time PCR containing SYBR Green fluorescent 
dye (Biodynamics SRL, Buenos Aires, Argentina). qPCR 
reactions were carried out in an Applied Biosystems 
7500. Primers sequences (Biodynamics SRL, Buenos 
Aires, Argentina), were designed using Primer Express 
software version 3.0 (Applied Biosystems, California, 
USA). Quantification of the target gene expression was 
done using the comparative cycle threshold (Ct) method 
according to the manufacturer’s instructions (Applied 
Biosystems, California, USA). An average Ct was 
obtained from the triplicate reactions and normalized to 
β2-microglobulin and then DDCt was calculated. 
Human primers Sequence (5′-3′): cyp3A4 fw 
cattcctcatcccaattcttgaagt; cyp3A4 rv ccactcggtgcttttgtg 
tatct; cyp3A5 fw gctcgcagcccagtcaata; cyp3a5 rv aggtggtgc 
cttattgggc; cyp3A7 fw aagggctattggacgtttgaca; cyp3A7 
rv atcccactggcccgaaag; cyp3A43 fw aatacgaacattgctatctc 
cagct; cyp3A43 rv gcttctcaccaacatatctccacat; ITGAV fw 
aagtgccatagctccattgggaga; ITGAV rv tcgaggatttgagatg 
gcaccgaa; ITGB3 fw ttcaatgccacctgcctcaacaac; ITGB3 rv 
acgcaccttggcctcgatactaaa; TRa fw ctgatccacattgccacaga; 
TRa rv ttccaggtccaccttgtctc; B2M fw agatgagtatgcct 
gccgtgtgaa; B2M rv tgctgcttacatgtctcgatccca.
Murine primers Sequence (5′-3′): cyp1a1 fw 
ataaggtcatcacgattgttttgg; cyp1a1 rv ggtacatgaggctccac 
gagat; cyp1a2 fw cgtcagcaagcttcagaagg; cyp1a2 rv 
cgatgttcagcatctcctcg; cyp2b10 fw caggtgatcggctcacacc; 
cyp2b10 rv caggtgatcggctcacacc; cyp3a11 fw tcacacacaca 
gttgtagggagaa; cyp3a11 rv gtccatccctgcttgtttgtc; B2M fw 
gctatccagaaaacccctcaa; B2M rv catgtctcgatcccagtagacggt.
Immunoblotting
Samples of Jurkat cells lysates were prepared as 
previously described [8]. Equal amounts of proteins 
(50 μg) were separated by SDS–PAGE on 10% 
polyacrylamide gels and transferred to nitrocellulose 
membranes. Nonspecific binding sites were blocked with 
blocking buffer (5% nonfat dried milk in PBS 0.1% Tween 
20). Membranes were incubated overnight at 4° C with a 
primary antibody CYP3A4, pStat1-Y701, Stat1, GAPDH 
and β-tubulin (Santa Cruz) pNF-κB-S536 (Cell Signaling). 
Secondary mouse or rabbit HRP-conjugated antibody 
(Santa Cruz Biotechnology) were incubated for 1h at 
room temperature. AmershamTM ECL™ Prime Western 
blotting detection reagent (GE Healthcare) was used 
to develop the protein blot. Blots were developed using 
ImageQuant LAS 4000 (GE Health Care). Densitometry 
analysis was performed by Image J (version 5.1, Silk 
Scientific Corporation, NIH, Bethesda, MA) software. 
Experimental values were referred to those obtained with 
the corresponding loading protein band.
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CYP3A4 activity assay
CYP3A4 activity assay was performed using the 
commercial kit P450 Glo (Promega) according to the 
manufacturer´s protocol. Briefly, cells were cultured in 
presence or absence of THs and inhibitors for 48 hours. 
Then the corresponding Luciferin and the Luminiscence 
detection reagent were added for the indicated time 
and luminescence was measured using a luminometer 
(NovoStar microplate reader, BMG Labtech).
Confocal microscopy in cell cultures
Confocal microscopy analysis was performed as 
previously described [8]. Briefly, prior to incubation 
with the primary antibody (T701-Stat1, sc5808, Santa 
Cruz Biotechnology) cells were first fixed in cold 
methanol for at least 30 minutes, permeabilized with 
0.1% Triton-PBS for 20 minutes and incubated overnigth 
at 4° C. Then cells were washed and incubated for 
30 minutes with the secondary antibody, anti-rabbit-
FITC (ab6717, Abcam). Nucleus compartment was 
defined by Propidium Iodide staining for 1 minute 
(0,02 mg/ml). Cells were analyzed with a Nikon Eclipse 
E800 confocal laser microscopy system.
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